DE60334076D1 - Monoklonaler anti-mensch-tenascin-Antikörper - Google Patents

Monoklonaler anti-mensch-tenascin-Antikörper

Info

Publication number
DE60334076D1
DE60334076D1 DE60334076T DE60334076T DE60334076D1 DE 60334076 D1 DE60334076 D1 DE 60334076D1 DE 60334076 T DE60334076 T DE 60334076T DE 60334076 T DE60334076 T DE 60334076T DE 60334076 D1 DE60334076 D1 DE 60334076D1
Authority
DE
Germany
Prior art keywords
monoclonal anti
human tenascin
tenascin antibody
antibody
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60334076T
Other languages
German (de)
English (en)
Inventor
Santis Rita De
Anna Maria Anastasi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Application granted granted Critical
Publication of DE60334076D1 publication Critical patent/DE60334076D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60334076T 2002-02-26 2003-02-20 Monoklonaler anti-mensch-tenascin-Antikörper Expired - Lifetime DE60334076D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35929902P 2002-02-26 2002-02-26
PCT/IT2003/000098 WO2003072608A1 (en) 2002-02-26 2003-02-20 Anti-human tenascin monoclonal antibody

Publications (1)

Publication Number Publication Date
DE60334076D1 true DE60334076D1 (de) 2010-10-21

Family

ID=27766061

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60334076T Expired - Lifetime DE60334076D1 (de) 2002-02-26 2003-02-20 Monoklonaler anti-mensch-tenascin-Antikörper

Country Status (19)

Country Link
US (3) US7438908B2 (enExample)
EP (1) EP1478667B1 (enExample)
JP (1) JP4488746B2 (enExample)
KR (1) KR101048894B1 (enExample)
CN (1) CN1317303C (enExample)
AR (1) AR038700A1 (enExample)
AT (1) ATE480564T1 (enExample)
AU (1) AU2003215900B2 (enExample)
BR (1) BR0307994A (enExample)
CA (1) CA2475395C (enExample)
CY (1) CY1111108T1 (enExample)
DE (1) DE60334076D1 (enExample)
DK (1) DK1478667T3 (enExample)
ES (1) ES2352180T3 (enExample)
MX (1) MXPA04008216A (enExample)
PL (1) PL213216B1 (enExample)
PT (1) PT1478667E (enExample)
SI (1) SI1478667T1 (enExample)
WO (1) WO2003072608A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20040105A1 (it) 2004-02-27 2004-05-27 Tecnogen Scpa Anticorpo monoclonale antitenascina umana.
US8586716B2 (en) 2006-08-04 2013-11-19 Novartis Ag EPHB3-specific antibody and uses thereof
US10416162B2 (en) 2007-12-20 2019-09-17 Monogram Biosciences, Inc. Her2 diagnostic methods
FR2930036B1 (fr) * 2008-04-11 2010-05-07 Assist Publ Hopitaux De Paris Procede de diagnostic d'une hypertension arterielle pulmonaire.
WO2010002862A2 (en) * 2008-07-01 2010-01-07 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (fgfr3) binding proteins
WO2010065568A2 (en) 2008-12-01 2010-06-10 Laboratory Corporation Of America Holdings METHODS AND ASSAYS FOR MEASURING p95 AND/OR p95 IN A SAMPLE AND ANTIBODIES SPECIFIC FOR p95
EP2387717B1 (en) * 2009-01-15 2014-12-10 Laboratory Corporation of America Holdings Methods of determining patient response by measurement of her-2 expression
SG172983A1 (en) 2009-01-15 2011-08-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-3
US10266585B2 (en) 2009-08-28 2019-04-23 The Board Of Regents Of The Univerity Of Texas System Methods of treating brain injury
WO2011060076A1 (en) * 2009-11-10 2011-05-19 Amgen Inc. Anti-c-mpl antibodies
CA2817973C (en) * 2010-10-15 2019-06-25 The Board Of Regents Of The University Of Texas System Antibodies that bind amyloid oligomers
US8959638B2 (en) 2011-03-29 2015-02-17 Mcafee, Inc. System and method for below-operating system trapping and securing of interdriver communication
US9317690B2 (en) 2011-03-28 2016-04-19 Mcafee, Inc. System and method for firmware based anti-malware security
US9262246B2 (en) 2011-03-31 2016-02-16 Mcafee, Inc. System and method for securing memory and storage of an electronic device with a below-operating system security agent
US8863283B2 (en) 2011-03-31 2014-10-14 Mcafee, Inc. System and method for securing access to system calls
US9087199B2 (en) 2011-03-31 2015-07-21 Mcafee, Inc. System and method for providing a secured operating system execution environment
US8966629B2 (en) 2011-03-31 2015-02-24 Mcafee, Inc. System and method for below-operating system trapping of driver loading and unloading
US8813227B2 (en) 2011-03-29 2014-08-19 Mcafee, Inc. System and method for below-operating system regulation and control of self-modifying code
US8966624B2 (en) 2011-03-31 2015-02-24 Mcafee, Inc. System and method for securing an input/output path of an application against malware with a below-operating system security agent
US9032525B2 (en) 2011-03-29 2015-05-12 Mcafee, Inc. System and method for below-operating system trapping of driver filter attachment
US8925089B2 (en) 2011-03-29 2014-12-30 Mcafee, Inc. System and method for below-operating system modification of malicious code on an electronic device
US9038176B2 (en) 2011-03-31 2015-05-19 Mcafee, Inc. System and method for below-operating system trapping and securing loading of code into memory
US9255595B2 (en) * 2011-04-29 2016-02-09 Bae Systems Information And Electronic Systems Integration Inc. Optical dome bezel
JP6158825B2 (ja) * 2011-12-12 2017-07-05 オックスフォード ユニヴァーシティ イノヴェーション リミテッド テネイシンｃおよび関節リウマチにおけるその使用
DK2968503T3 (en) * 2013-03-15 2018-12-03 Intrinsic Lifesciences Llc ANTI-HEPCIDIN ANTIBODIES AND APPLICATIONS THEREOF
GB201414021D0 (en) * 2014-08-07 2014-09-24 Nascient Ltd Biological materials and uses thereof
EP3197915A4 (en) 2014-09-22 2018-12-19 Intrinsic Lifesciences LLC Humanized anti-hepcidin antibodies and uses thereof
GB201602413D0 (en) * 2016-02-10 2016-03-23 Nascient Ltd Method

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687732A (en) 1983-06-10 1987-08-18 Yale University Visualization polymers and their application to diagnostic medicine
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994021293A1 (en) 1993-03-19 1994-09-29 Duke University Method of treatment of tumors with an antibody binding to tenascin
US5482698A (en) 1993-04-22 1996-01-09 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin polymer conjugates
ATE335072T1 (de) 1993-05-28 2006-08-15 Scripps Research Inst Methoden für inhibition der cd14-abhängigen zellaktivierung
US6335014B1 (en) 1998-06-17 2002-01-01 The Institute Of Physical And Chemical Research Medicament for suppressing cancer metastasis
ITRM20020128A1 (it) 2002-03-08 2003-09-08 Sigma Tau Ind Farmaceuti Dimeri di avidina efficaci nell'incrementare la concentrazione di biotina radioattiva nella immunoterapia con "pretargeting".

Also Published As

Publication number Publication date
SI1478667T1 (sl) 2010-12-31
WO2003072608A1 (en) 2003-09-04
CN1317303C (zh) 2007-05-23
EP1478667A1 (en) 2004-11-24
CN1639192A (zh) 2005-07-13
AU2003215900A1 (en) 2003-09-09
KR20040086426A (ko) 2004-10-08
AR038700A1 (es) 2005-01-26
PL372803A1 (en) 2005-08-08
US8048417B2 (en) 2011-11-01
ES2352180T3 (es) 2011-02-16
PL213216B1 (pl) 2013-01-31
JP4488746B2 (ja) 2010-06-23
DK1478667T3 (da) 2010-12-20
BR0307994A (pt) 2004-12-07
JP2005534615A (ja) 2005-11-17
US7438908B2 (en) 2008-10-21
EP1478667B1 (en) 2010-09-08
CA2475395A1 (en) 2003-09-04
PT1478667E (pt) 2010-12-09
AU2003215900B2 (en) 2008-09-25
MXPA04008216A (es) 2004-11-26
KR101048894B1 (ko) 2011-07-13
US20110020219A1 (en) 2011-01-27
CY1111108T1 (el) 2015-06-11
HK1078589A1 (en) 2006-03-17
CA2475395C (en) 2011-08-02
ATE480564T1 (de) 2010-09-15
US20040005643A1 (en) 2004-01-08
US20050106145A1 (en) 2005-05-19

Similar Documents

Publication Publication Date Title
DK1478667T3 (da) Monoklonalt anti-humant tenascin-antistof
DE60222658D1 (de) Monoklonaler anti-cd-40-antikörper
EE200300179A (et) Humaniseeritud LT-ß-R-i vastased antikehad
EP1490110A4 (en) ANTI-ALPHA V BETA 6 ANTIBODIES
CY2012019I1 (el) Ανθρωπινα μονοκλωνα αντισωματα εναντια στο cd20
DK1501856T3 (da) Anti-HER2 antistofvarianter
EP1499352A4 (en) ANTI-INTERLEUKIN-9 RECOMBINANT ANTIBODIES
AU2003264009A8 (en) Humanized rabbit antibodies
IS6982A (is) Mótefni gegn VLA-1
EP1607404A4 (en) MONOCLONAL ANTIBODY AND HYBRIDOM THAT PRODUCES THIS
DK1599504T3 (da) Modificeret antistof
DE602004022855D1 (de) Interleukin-10-antikörper
HRP20151252T1 (xx) Modificirani fab ulomci protutijela
EP1567555A4 (en) HUMANIZED ANTIBODIES AGAINST CHEMOTOXIC MONOCYTE PROTEINS
EE200300569A (et) CD44v6-spetsiifilised antikehad
BRPI0509495A2 (pt) anticorpo humanizado
PT1718678T (pt) Anticorpo monoclonal de tenascina anti-humano
NO20044145L (no) Assay for anti-INGAP antistoffer
FI20020807A0 (fi) Uusia humanisoituja anti-VAP-1 monoklonaalisia vasta-aineita
FI20011055A0 (fi) Heveiiniä sitovat monoklonaaliset vasta-aineet
EP1483292A4 (en) MONOCLONAL ANTIBODIES WITH CROSS-REACTION AGAINST BACTERIAL COLLAGEN BINDING PROTEINS
ITPD20000192A0 (it) Anticorpi policlonali
EP1712564A4 (en) MONOCLONAL ANTI-NC1 ANTIBODY
DK1503799T3 (da) Immunogent, monoklonalt antistof
GB0415644D0 (en) Monoclonal antibody